APA

Röth A., Rottinghaus S. T., Hill A., Bachman E. S., Kim J. S., Schrezenmeier H., Terriou L., Urbano-Ispizua Á., Wells R. A., Jang J. H., Kulasekararaj A. G., Szer J., Aguzzi R., Damokosh A. I., Shafner L. & Lee J. W. (20190828). Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. : Blood advances.

Chicago

Röth Alexander, Rottinghaus Scott T, Hill Anita, Bachman Eric S, Kim Jin Seok, Schrezenmeier Hubert, Terriou Louis, Urbano-Ispizua Álvaro, Wells Richard A, Jang Jun Ho, Kulasekararaj Austin G, Szer Jeff, Aguzzi Rasha, Damokosh Andrew I, Shafner Lori and Lee Jong Wook. 20190828. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. : Blood advances.

Harvard

Röth A., Rottinghaus S. T., Hill A., Bachman E. S., Kim J. S., Schrezenmeier H., Terriou L., Urbano-Ispizua Á., Wells R. A., Jang J. H., Kulasekararaj A. G., Szer J., Aguzzi R., Damokosh A. I., Shafner L. and Lee J. W. (20190828). Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. : Blood advances.

MLA

Röth Alexander, Rottinghaus Scott T, Hill Anita, Bachman Eric S, Kim Jin Seok, Schrezenmeier Hubert, Terriou Louis, Urbano-Ispizua Álvaro, Wells Richard A, Jang Jun Ho, Kulasekararaj Austin G, Szer Jeff, Aguzzi Rasha, Damokosh Andrew I, Shafner Lori and Lee Jong Wook. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. : Blood advances. 20190828.